Evofem Biosciences, Inc. · OTC:EVFM

Evofem Biosciences — Stifel Virtual Healthcare Conference 2020

11 slides from Evofem Biosciences's conference presentation, Nov 18, 2020

  1. Slide 1: Revolutionizing Women's Sexual and Reproductive Health

    Revolutionizing Women’s Sexual and Reproductive Health Saundra Pelletier, CEO Stifel Virtual Healthcare Conference November 18, 2020 NASDAQ: EVFM For investor discussions only. 1 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. In some cases, you can identify forward looking statements by terms such as “may,” ”will,” “should,” “expect,

  3. Slide 3: Evofem Biosciences 101

    Evofem Biosciences 101 • Commercial-stage biopharmaceutical company • Mission: to improve women’s lives by developing and commercializing innovative prescription products to address critical unmet needs in women’s sexual and reproductive health • Launched Phexxi® in September 2020 o First-and-only F

  4. Slide 4: Phexxi is Off to a Strong Start: Encouraging October Data

    Phexxi® is Off to a Strong Start Encouraging October Data • Monthly TRx and NRx growing • Number of unique Phexxi prescribers more than doubled versus September o Geographically diverse o Over 800 unique HCPs prescribed Phexxi from launch through October • Over 1/3 of Phexxi prescribers have written

  5. Slide 5: Phexxi is Off to a Strong Start: Building Awareness

    Phexxi® is Off to a Strong Start Building Awareness • 650,000 visits to consumer site1 • Strong engagement driving conversions on HCP-Phexxi.com 2 o 31k unique visitors, 53k page views • Successfully harnessing social media that resonates with our key audience segments 1 o ~250M social media impress

  6. Slide 6: Telehealth Platform is Exceeding Expectations

    Phexxi® Telehealth Platform is Exceeding Expectations 41% of women who qualified for Phexxi through our Phexxi Concierge Service have requested a Phexxi prescription Populus Media: “Phexxi is our most successful launch to date” Source: Populus AWS – 15 Nov 2020 For investor discussions only. 6 ©©201

  7. Slide 7: Concierge Recruitment Platform with Nurse Support Driving Significant Leads

    Phexxi® Concierge Recruitment Platform with Nurse Support Driving Significant Leads Harnessing AI to generate high-quality leads • 83Bar metrics projected generation of 200 leads/month • Consistently generating over 200 leads/week o 4x to 5x higher than expectations • ~75% of women who engaged have

  8. Slide 8: Market Access: Positive Coverage Trends

    Market Access: Positive Coverage Trends • 55% of commercial lives covered • Unique classification in the payor-utilized pricing compendiums First Data Bank and Medispan as “Vaginal pH Modulator” allowing for favorable reimbursement • Phexxi on preventative drug list at $0 cost-share with many promin

  9. Slide 9: $2.3 Billion Peak Revenue Potential

    $2.3 BILLION Peak Revenue Potential US Contraceptive Market: 72.2M Women1 Primary Targets 360k – 460k Non-Rx 3.5% - 4.5%2 users $670M - $860M Contraceptive Users + 10.3M Primary Targets 200k – 370k $375M - $690M Sterilization, other No 2.0% - 3.5%2 users non-targets - Contraceptive - 32.5M 10.6M + S

  10. Slide 10: Favorable Data from Post-Concierge Surveys

    Favorable Data from Post-Concierge Surveys Survey of 127 Women Conducted 30 Days After They Entered into the Phexxi Concierge Experience Product Attributes Underlying Decision to Move Forward with Phexxi1 of women who used Hormone-free Phexxi reported they will 89% refill their prescription2 Doesn't

  11. Slide 11: ®

    ® 11 ©©2019 2020 EvofemEvofem Biosciences,Biosciences, Inc.Inc.

Evofem Biosciences — Stifel Virtual Healthcare Conference 2020 on 6ix